Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(2s), 63-67 | ISSN:2251-6727

Genetic Profiling of Skin Cancers: Implications for Targeted Therapies

[1]Dr Jamale Varsha, [2]Dr Nikhil Girish, [3]Dr Balkrishna Nikam, [4]Dr Mohak Arora

[1]Associate Professor Department of dermatology Krishna Institute of Medical Sciences Krishna Vishwa Vidyapeeth, Karad
[2]Resident Department of dermatology Krishna Institute of Medical Sciences Krishna Vishwa Vidyapeeth, Karad
[3]Associate Professor Department of dermatology Krishna Institute of Medical Sciences Krishna Vishwa Vidyapeeth, Karad
[4]Resident Department of dermatology Krishna Institute of Medical Sciences Krishna Vishwa Vidyapeeth, Karad

KEYWORDS
Melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC), skin cancer, genetic, development and progression.

ABSTRACT:
Skin cancer is a common and growing global health problem that has many different subtypes, each of which has its own aetiology and genetic makeup. The three most common kinds of skin cancer are melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC), and new genetic research has revealed a spectrum of genetic variants underpinning their genesis and spread. BRAF and NRAS mutations play major roles in melanoma, activating important carcinogenic pathways and offering important therapeutic targets. The development of immune checkpoint inhibitors and BRAF inhibitors has altered melanoma treatment paradigms, improving patient outcomes. SCC has unique genetic characteristics that promote unchecked cell proliferation and differentiation, including TP53 and NOTCH1 mutations. Immune checkpoint inhibitors like pembrolizumab and treatments that modulate the NOTCH pathway have potential for the treatment of SCC. The PTCH1 and SMO gene mutations that activate the Hedgehog pathway and create the distinctive genomic landscape of BCC. The therapy of BCC has been transformed by hedgehog pathway inhibitors like vismodegib, which provide a personalised method based on genetic profiles. Our understanding of the molecular pathways behind skin malignancies has grown thanks to genetic profiling, which also has implications for early detection and prognosis evaluation. Genetic markers support accurate diagnosis, aid in risk assessment, and direct individualised treatment plans. There are still difficulties including intra-tumoral heterogeneity and resistance to targeted therapy. The dynamic science of genetics is still developing, giving rise to optimism for more individualised and efficient ways to treat skin cancers and, ultimately, lessening the burden of these malignancies.

INTRODUCTION

A serious and prevalent public health problem, skin cancer has many subtypes, each with a unique aetiology and set of genetic traits. Recent genomic research has found a remarkable array of genetic variants in cancers ranging from the most lethal type, melanoma, to the common squamous cell carcinoma (SCC), and basal cell carcinoma (BCC), providing enormous prospects for precision therapy. Genetic profiling has become a pillar in the search for efficient targeted therapeutics as a result of the effort to comprehend and utilise these genetic profiles [1-3].

With an increasing frequency, skin cancer is an international threat. The main environmental risk factor for developing skin cancer is ultraviolet (UV) radiation, which causes genetic abnormalities that give rise to many skin malignancies. With more than five million cases identified each year, skin cancer is the most prevalent malignancy in the United States alone. This highlights the urgent need for a deeper comprehension of the genetic roots of these cancers in order to develop more efficient therapeutic approaches [4-6].

Infamously aggressive and prone to metastasizing, melanoma is a cancer that develops in melanocytes. Recent genomic studies have shed light on the complex

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(2s), 63-67 | ISSN:2251-6727

genetic landscape of melanoma, revealing a range of mutations and aberrations that are responsible for the disease's onset and spread. BRAF and NRAS gene mutations have received the most attention among these. The MAPK signalling pathway is activated by BRAF mutations, particularly the V600E mutant, which promotes unchecked cell proliferation [7-10]. By encouraging cell survival and proliferation, NRAS mutations also play a significant part in the development of melanoma. The understanding of these genetic changes has opened up new possibilities for the treatment of melanoma.

These genetic discoveries have important ramifications. Targeted medicines that take advantage of these genetic markers have revolutionised the treatment of melanoma. In clinical trials, BRAF inhibitors like vemurafenib and dabrafenib have shown exceptional efficacy, improving outcomes and survival rates in patients with BRAF mutations [2, 8]. Additionally, immune checkpoint inhibitors like pembrolizumab and nivolumab, which enable the immune system to recognise and eliminate cancer cells, have demonstrated outstanding benefits in melanoma patients. These discoveries highlight the crucial role that genetic screening plays in influencing therapy choices for melanoma patients.

MELANOMA GENETIC VARIATIONS

Melanoma presents a fascinating environment for genetic research because of its aggressiveness and genetic complexity. Melanoma has a variety of mutations and genetic changes that contribute to the growth and spread of the disease, according to genetic profiling.

The majority of melanoma mutations are BRAF mutations, particularly the V600E variant, which accounts for 50% of occurrences. The V600E mutation causes the MAPK signalling pathway to become constitutively active, which promotes unchecked cell proliferation and tumour formation [3]. Melanoma cases with NRAS mutations make up about 20% of all cases. Through the RAS/RAF/MEK/ERK pathway, NRAS mutations increase downstream signalling, which aids in cell survival and proliferation [4]. It is essential to comprehend these genetic changes since it paves the path for the creation of tailored treatments.

BRAF inhibitors have gained popularity among melanoma targeted therapy. In clinical studies, the drugs vemurafenib and dabrafenib, which are intended to selectively target the mutant BRAF protein, have demonstrated astounding success. These medications prolong survival in patients with the V600E mutation and significantly reduce tumour growth [5]. They do this by inhibiting the oncogenic signalling that the V600E mutation drives. By limiting the development of drug resistance, the use of BRAF inhibitors in combination with MEK inhibitors, such as trametinib, has further improved treatment results [6].

Immune checkpoint drugs, in addition to BRAF inhibitors, have completely changed how melanoma is treated. Targeting the programmed cell death protein 1 (PD-1) receptor, pembrolizumab and nivolumab enable the patient's immune system to identify and destroy cancer cells. Even in individuals with advanced illness, these immunotherapies have shown exceptional melanoma response rates and durability [7]. To maximise therapeutic success, combinations of immunotherapies and targeted treatments are also being investigated.

Targeted therapeutics and the study of melanoma genetics continue to face obstacles. Most patients eventually acquire resistance to BRAF inhibitors, necessitating the investigation of innovative medication combinations to get over this obstacle. Additionally, finding uncommon and poorly understood genetic changes in melanoma is crucial as these could present unexplored therapy possibilities. Targeted therapy for melanoma is still developing, and this gives promise for more developments and better patient care.

MOLECULAR SIGNATURES IN SQUAMOUS CELL CARCINOMA

A frequent type of skin cancer called squamous cell carcinoma (SCC) differs from melanoma and basal cell carcinoma (BCC) in that it has a distinctive genetic makeup. Specific molecular signals that drive SCC formation and progression have been revealed by genetic profiling.

The genetic changes seen in this cancer are primarily caused by TP53 mutations, which are common in SCC. A tumour suppressor protein that controls cell proliferation and apoptosis is encoded by the TP53 gene. TP53 mutations in SCC are in charge of encouraging unchecked cell proliferation and preventing cell death [8]. The NOTCH1 gene, which is important in cell differentiation and tissue homeostasis, has a mutation,

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(2s), 63-67 | ISSN:2251-6727

which is another prominent genetic change found in SCC. The deregulation of keratinocyte differentiation, a hallmark of SCC formation, has been linked to NOTCH1 mutations [9].

The possibility of new therapy strategies for SCC exists with better understanding of these genetic abnormalities. Targeting the NOTCH pathway is one such strategy. The effectiveness of novel medicines intended to alter the NOTCH pathway in the treatment of SCC is being studied. These treatments constitute a viable approach for targeted interventions in SCC since they attempt to restore correct keratinocyte differentiation and stop tumour growth [10].

Immune checkpoint inhibitors, such as pembrolizumab and cemiplimab, have shown significant outcomes in advanced SCC patients in addition to NOTCH pathway-targeted treatments. These immunotherapies improve the patient's immune system's capacity to identify and combat cancer cells by inhibiting PD-1 receptor signalling. In patients with advanced SCC, this has resulted in substantive clinical responses [11].

However, in the context of genetic profiling and targeted treatments, SCC poses its particular difficulties. It is crucial to keep deciphering the complexity of this malignancy because the genetic landscape of SCC is less clearly understood than that of melanoma. A concern is still raised by acquired resistance to immunotherapies and targeted medicines. To enhance treatment outcomes for SCC patients, future research should concentrate on improving therapeutic approaches and discovering more genetic markers.

GENETIC UNDERSTANDINGS OF BASAL CELL CARCINOMA

The most common form of skin cancer, basal cell carcinoma (BCC), is notable for its genetic makeup and possibility for targeted therapy. Significant advances in the knowledge and treatment of BCC have been made thanks to genetic profiling of this malignancy.

BCC commonly exhibits dysregulation of the Hedgehog pathway, a crucial regulator of cell proliferation and differentiation. The PTCH1 and SMO genes, which encode proteins that regulate the Hedgehog pathway, are the main causes of this dysregulation. Mutations in PTCH1 and SMO activate the pathway in a constitutive manner, which promotes unchecked cell division and tumour formation [12].

The genomic insights provided by BCC have clear therapeutic ramifications. Vismodegib and sonidegib are examples of Hedgehog pathway inhibitors that have changed the way BCC patients are treated. These inhibitors successfully block the dysregulated pathway, which results in tumour reduction and better results. A major progress in the treatment of BCC was made with Vismodegib, which was the first Hedgehog pathway inhibitor to receive FDA approval for use in advanced or metastatic BCC [13].

Personalised therapeutic options are now available for BCC patients thanks to genetic analysis. Clinicians can customise treatment regimens to each patient's unique genetic profile by identifying the particular mutations that exist within the Hedgehog pathway. This strategy aims to reduce side effects while maximising treatment efficacy.

In spite of these developments, there are still problems with BCC research and therapy. The development of resistance to Hedgehog pathway inhibitors makes the investigation of combination therapy and innovative pharmacological approaches necessary. Additionally, there is continuing investigation towards the discovery of uncommon genetic changes in BCC. However, the genetic knowledge discovered thus far shows significant potential for improving the treatment of BCC and lessening the incidence of this widespread skin cancer.

IMPLICATIONS OF GENETIC PROFILING FOR DIAGNOSIS AND OUTLOOK

In addition to providing insights into the molecular underpinnings of these malignancies, genetic profiling in skin cancer has important ramifications for early diagnosis and prognostic evaluation. Finding particular genetic markers can help with early discovery, offer useful prognostic data, and give a clearer picture of how the disease develops.

Genetic profiling can help identify those who are more likely to acquire skin cancer in the setting of early detection. For instance, people who have a family history of melanoma or certain genetic predispositions, such as germline CDKN2A mutations, may be more prone to the disease. These genetic markers can be utilised to determine risk, leading to heightened surveillance and preventative measures for those who are at risk [14].

Additionally, the existence of specific genetic mutations can offer crucial diagnostic data. BRAF mutations,

especially the V600E mutant, are not only a therapeutic target but also a diagnostic sign in melanoma. These mutations can be found in tumour tissue or through liquid biopsies, which can help to support the diagnosis of melanoma and direct treatment choices [15].

An additional crucial component of controlling skin cancer is prognosis assessment. The anticipated course and potential outcomes of the disease can be revealed through genetic profiling. For instance, it has been discovered that specific genetic abnormalities, such as BRAF mutations or a high mutational burden, are linked to a worse prognosis and a higher probability of metastasis in melanoma [16]. Clinicians can modify surveillance and treatment plans by taking these genetic indicators into account.

The use of genetic data into clinical practise is becoming more and more crucial as genetic profiling develops. In addition to improving patient care, the discovery of genetic markers for early detection and prognosis evaluation also helps healthcare organisations allocate resources more effectively. In the end, the implications of genetic profiling for diagnosis and prognosis have the potential to enhance patient outcomes and lessen the prevalence of skin malignancies.

CHALLENGES AND FUTURE DIRECTIONS

While genetic sequencing has significantly advanced our understanding and treatment of skin malignancies, there are still a number of obstacles to overcome and exciting new possibilities to explore.

The intra-tumoral heterogeneity seen in skin malignancies, particularly melanoma, presents a significant obstacle. When different genetic mutations are present within a single tumour, this is referred to as intra-tumoral heterogeneity. This complexity can make treatment choices more difficult and increase a patient's resistance to therapy. To better comprehend the complex genetic environment present in tumours and provide more potent treatments, approaches to address intra-tumoral heterogeneity, including as single-cell sequencing and spatial transcriptomics, are now being investigated [17].

The emergence of resistance to targeted therapy, particularly in melanoma, is another difficulty. While immune checkpoint inhibitors and BRAF inhibitors have demonstrated extraordinary success, resistance can develop, reducing their long-term efficacy. To combat this resistance and enhance patient outcomes, research is being done on combination therapy, such as BRAF and MEK inhibitor combos. Novel treatments that target various molecular pathways are also being developed to give patients access to more therapy alternatives.

A persistent focus is the discovery of uncommon and poorly understood genetic changes in skin malignancies. Given the dynamic nature of genetics, ongoing efforts are required to identify new genetic markers that can offer fresh perspectives and therapeutic options. Our understanding of the genetic basis of skin malignancies has the potential to be significantly enhanced by developments in high-throughput sequencing technology and the creation of extensive genomic databases.

CONCLUSION

Finally, the genetic profiling of skin cancers has altered how we think about these tumours and paved the way for cutting-edge targeted treatments. Each type of cancer has a distinct genetic makeup, and certain mutations can be used as therapeutic targets in melanoma, SCC, and BCC. These genetic discoveries have implications for early diagnosis, prognosis evaluation, and individualised treatment plans. However, issues like intra-tumoral heterogeneity and therapy resistance continue, compelling researchers to investigate cutting-edge treatment approaches. The dynamic science of genetics offers hope for more efficient and specialised approaches in the fight against skin malignancies in the future.

REFERENCES

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
2. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol. 2011;8(7):426-433.
3. Pickering CR, Zhou JH, Lee JJ, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014;20(24):6582-6592.
4. Xie J, Murone M, Luoh SM, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391(6662):90-92.
5. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell

carcinoma. N Engl J Med. 2012;366(23):2171-2179.

6. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
7. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535-1546.
8. Freedberg, I.M., Fitzpatrick, T.B. Fitzpatrick's Dermatology in General Medicine. 5th ed. McGraw-Hill, 1999.
9. South AP, Purdie KJ, Watt SA, et al. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. J Invest Dermatol. 2014;134(10):2630-2638.
10. Nowell CS, Radtke F. Notch as a tumour suppressor. Nat Rev Cancer. 2017;17(3):145-159.
11. Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341-351.
12. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743-754.
13. De Giorgi V, Scarfì F, Trane L, et al. Treatment of Advanced Basal Cell Carcinoma with Hedgehog Pathway Inhibitors: A Multidisciplinary Expert Meeting. Cancers (Basel). 2021;13(22):5706. Published 2021 Nov 15. doi:10.3390/cancers13225706.
14. Haugh AM, Njauw CN, Bubley JA, et al. Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature. JAMA Dermatol. 2017;153(10):999-1006. doi:10.1001/jamadermatol.2017.2330.
15. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-714.
16. Siroy AE, Boland GM, Milton DR, et al. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015;135(2):508-515.
17. Tirosh I, Izar B, Prakadan SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352(6282):189-196.